HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.
about
Current Advances in Virus-Like Particles as a Vaccination Approach against HIV InfectionStructure-Based Design of a Protein Immunogen that Displays an HIV-1 gp41 Neutralizing EpitopeAntibody-Mediated Fcγ Receptor-Based Mechanisms of HIV Inhibition: Recent Findings and New Vaccination StrategiesThe development of an AIDS mucosal vaccine.Recombinant expression, purification, and biophysical characterization of the transmembrane and membrane proximal domains of HIV-1 gp41.Targeting Trojan Horse leukocytes for HIV prevention.Induction of Potent and Long-Lived Antibody and Cellular Immune Responses in the Genitorectal Mucosa Could be the Critical Determinant of HIV Vaccine Efficacy.HIV Infection and Gut Mucosal Immune Function: Updates on Pathogenesis with Implications for Management and Intervention.Which Antibody Functions are Important for an HIV Vaccine?The mouth: a gateway or a trap for HIV?Mucosal correlates of protection in HIV-1-exposed sero-negative persons.Immune responses to HIV and SIV in mucosal tissues: 'location, location, location'.HIV-1 specific IgA detected in vaginal secretions of HIV uninfected women participating in a microbicide trial in Southern Africa are primarily directed toward gp120 and gp140 specificitiesMultiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.Dendritic cell status modulates the outcome of HIV-related B cell disease progression.Phase I randomised clinical trial of an HIV-1(CN54), clade C, trimeric envelope vaccine candidate delivered vaginallyExpression, purification and crystallization of CTB-MPR, a candidate mucosal vaccine component against HIV-1.Mucosal immunity in the female genital tract, HIV/AIDSIsolation of HIV-1-neutralizing mucosal monoclonal antibodies from human colostrumIsotype modulates epitope specificity, affinity, and antiviral activities of anti-HIV-1 human broadly neutralizing 2F5 antibody.How can we design better vaccines to prevent HIV infection in women?Induction of immunity to human immunodeficiency virus type-1 by vaccination.Randomized Phase I: Safety, Immunogenicity and Mucosal Antiviral Activity in Young Healthy Women Vaccinated with HIV-1 Gp41 P1 Peptide on Virosomes.A nonparametric procedure for defining a new humoral immunologic profile in a pilot study on HIV infected patientsImmune responses to HIV in the female reproductive tract, immunologic parallels with the gastrointestinal tract, and research implicationsMolecular characterization of the cervical and systemic B-cell repertoire: Unique, yet overlapping, immune compartments of an HIV-1 resistant individual.Are anti-HIV IgAs good guys or bad guys?Is developing an HIV-1 vaccine possible?Scarcity or absence of humoral immune responses in the plasma and cervicovaginal lavage fluids of heavily HIV-1-exposed but persistently seronegative women.Biophysical Characterization of a Vaccine Candidate against HIV-1: The Transmembrane and Membrane Proximal Domains of HIV-1 gp41 as a Maltose Binding Protein FusionInfluence of dendritic cells on B-cell responses during HIV infection.Passively transmitted gp41 antibodies in babies born from HIV-1 subtype C-seropositive women: correlation between fine specificity and protection.Mother-to-Child HIV-1 Transmission Events Are Differentially Impacted by Breast Milk and Its Components from HIV-1-Infected Women.Modulation of immunogenicity and immunoprotection of mucosal vaccine against coxsackievirus B3 by optimizing the coadministration mode of lymphotactin adjuvantImmunological Characterization of Plant-Based HIV-1 Gag/Dgp41 Virus-Like Particles.New paradigms for HIV/AIDS vaccine development.Default in plasma and intestinal IgA responses during acute infection by simian immunodeficiency virus.Plasmid DNA Vaccine Co-Immunisation Modulates Cellular and Humoral Immune Responses Induced by Intranasal Inoculation in Mice.Anti-CD20 IgA can protect mice against lymphoma development: evaluation of the direct impact of IgA and cytotoxic effector recruitment on CD20 target cells.Strategies for eliciting HIV-1 inhibitory antibodies
P2860
Q26775082-C15D0B4F-F347-4511-8AFF-4A5E4D253808Q27675260-3682DD7E-C999-4359-91AB-ACD67A4915B9Q30408097-1A08BEAE-F4C2-4176-B815-F01B22860348Q30408103-102BD59C-E00B-4DBA-B298-10535B9B5E89Q30601090-9240FB32-283B-4679-B4EA-11CAF0B5BE33Q33518390-C9FBCB67-366E-408E-8A5E-D4C7EDB97054Q33611645-FA4856D6-318F-45BA-BA2B-2BFAE571F60AQ33651723-D286636B-DD48-4C31-8476-1C99F71721EEQ33772637-9BE48756-847B-4FFD-A648-98092E142819Q33874252-36A98D17-C5C0-49F9-B1F8-AE9323AEEE2AQ33911540-D73A2F67-CC19-4F9C-AD0E-90A06057E510Q33915790-430A3F29-EA21-47E8-AD40-E11CA6872185Q33939974-5FEB763A-F385-4243-93F4-F293C4989DFAQ33966586-F4818258-0799-4CD6-8EF8-51599F179784Q34013594-F5371FBB-A256-41DF-8521-EFE98F18BAFCQ34044915-26E58FF4-88E6-4AA7-A96B-4EE0392963D7Q34242643-43B51000-D6C3-4DB5-A546-64E276D8222AQ34275424-745200C1-840A-4172-BE0A-5E16F2FB7E61Q34280115-15E55AA1-A3ED-4909-AC94-8CA461FE30DAQ34283442-D027E2B6-A8F7-4840-BD39-4A5E1F124C3BQ34449068-F649395E-E5C8-4B6F-B9DF-1F532AF49828Q34540645-DF97F8E4-4B12-4027-BBC8-4B7C299A4714Q34598141-BF8A2850-BA5F-4CB6-8D25-85B742A28D6BQ34637668-18D3C04E-1A17-42CD-B402-61764E234D2BQ34712244-D528B50B-30DF-4A35-B343-BB426A6C50BFQ34974782-1B1357C5-0A61-4767-ACAA-492BC6CA5EB5Q34978880-9F74DAC6-8AE6-4922-85FE-F318645E0929Q35043547-0CB71924-0AAB-42E5-9D7F-8DD281D0E53FQ35093052-AD18F572-1626-490C-8AAF-D8DE9762265BQ35752124-FF4211DC-F891-4C00-9E25-30E51FFCCDFCQ35810658-25BAB8A8-977D-487E-95B9-C915FC84CD45Q35867981-02DA45D0-4448-4A93-B11C-5F710C3C3179Q35872338-A2EC95E0-3F1D-40CC-8D44-D15A9B4B7773Q35878371-26D55697-ABD4-4FAA-AE47-868CC5D1EBC0Q35960908-D253A9FF-776D-4268-A3A7-510DF245C342Q36011269-FD1ECF31-0FD2-40FF-AF6D-71B3681EBDE0Q36150291-310E61C5-4E10-4F6A-B804-2622FD3632CAQ36257975-7A6048BE-08A6-4DE4-9F42-481035E2E9A6Q36366594-87A71202-7472-4696-889E-2A534897679DQ36452155-7E8164B6-4E31-49C2-9516-1A6DA47AB75F
P2860
HIV-1 gp41-specific monoclonal mucosal IgAs derived from highly exposed but IgG-seronegative individuals block HIV-1 epithelial transcytosis and neutralize CD4(+) cell infection: an IgA gene and functional analysis.
description
2009 nî lūn-bûn
@nan
2009 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@ast
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@en
type
label
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@ast
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@en
prefLabel
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@ast
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@en
P2093
P2860
P356
P1433
P1476
HIV-1 gp41-specific monoclonal ...... gene and functional analysis.
@en
P2093
A-S Drillet
J-M Reynes
P2860
P2888
P304
P356
10.1038/MI.2009.89
P577
2009-07-08T00:00:00Z
P5875
P6179
1010151418